Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FMT plus apaloritovolrelizumab/fruquintinib in previously treated MSS/pMMR metastatic colorectal cancer
ChiCTR2500103366Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of fruquintinib and allogeneic fecal microbiota in colorectal adenocarcinoma and colorectal cancer (CRC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Median progression-free survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
fruquintiniballogeneic fecal microbiota
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500103366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103366.